Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Nephrology

Multidisciplinary Treatment Strategy

At a Glance

Calciphylaxis has no single proven treatment, so care usually requires a coordinated team. Treatment may combine sodium thiosulfate, expert wound care, pain control, calcium and phosphate management, and selected procedures, with close monitoring for treatment risks and infection.

Because calciphylaxis is a complex disease involving the kidneys, blood vessels, and skin, it cannot be treated by a single doctor or a single medication. Instead, the standard of care involves a multidisciplinary treatment strategy—a team of specialists working together to manage the disease [1][2].

It is important to understand that there is currently no single proven treatment protocol or “cure” for calciphylaxis [3]. Instead, doctors use a combination of off-label strategies based on expert consensus and observational evidence [4][3].

Your Care Team

A well-coordinated team is the foundation of your care. This team typically includes:

  • Nephrology: Manages your dialysis prescription and mineral balance [1].
  • Dermatology/Wound Care: Monitors skin progression and provides specialized local wound care [2].
  • Pain Management or Palliative Care: Focuses on aggressive pain control and improving your quality of life [5][6].
  • Nutrition (Renal Dietitian): Helps tailor your diet to your specific dialysis and healing needs [7].
  • Surgery: Evaluates wounds for potential removal of dead tissue or performs procedures on parathyroid glands if indicated [8].

Sodium Thiosulfate (STS)

Sodium Thiosulfate is the most common off-label treatment for calciphylaxis. It is thought to act as an antioxidant and may influence calcium deposits, though its exact mechanism is not fully proven [9].

Administration and Efficacy

  • How it is given: Protocols vary by local practice, patient weight, and dialysis status. For hemodialysis patients, it is frequently given intravenously during the final 30 to 60 minutes of dialysis sessions [10].
  • The Evidence: Research on STS is mixed. While observational case reports note improvements in pain and lesions, systematic reviews show that its benefit for overall survival remains inconclusive [11][12]. It is considered one option among many, not a guaranteed cure.

Serious Risks to Monitor

The most significant risk of STS is high-anion-gap metabolic acidosis—a potentially dangerous buildup of acid in your blood [13]. Your team will monitor your blood chemistry closely, specifically looking at your bicarbonate levels, anion gap, and fluid status. If you experience worsening nausea, vomiting, confusion, unusual weakness, or shortness of breath, contact your treatment team immediately. Only your treating team should adjust or stop STS dosing [14].

Wound Care and Debridement

The goal of wound care is to prevent infection and protect the tissue. Debridement involves the removal of dead or infected tissue to help a wound heal [15].

Decisions about debridement (whether surgical, bedside, or enzymatic) are highly individualized. They depend on the amount of necrosis, infection, local blood flow, your pain levels, and overall health. While prompt evaluation by an experienced wound or surgical team is essential, surgery is not the right answer for every wound; sometimes stable, dry eschar is carefully observed when healing potential is poor. You should never attempt to cut, pick, or debride the wound yourself [15][16].

Managing Mineral-Bone Disorder

Because imbalances in calcium and phosphate contribute to the disease, managing your kidney-related mineral bone disorder is crucial [17].

  • Cinacalcet (Calcimimetic): A medication that lowers parathyroid hormone (PTH) without increasing calcium. It is used in selected patients, with careful monitoring for low blood calcium [18][19].
  • Parathyroidectomy: Surgery to remove overactive parathyroid glands. Its specific benefit for calciphylaxis is uncertain and individualized. It carries high surgical risks, including hungry bone syndrome—a profound, rapid drop in blood calcium levels after surgery that requires intensive monitoring [16][20].

Hyperbaric Oxygen Therapy (HBOT)

In HBOT, you breathe 100% oxygen inside a pressurized chamber. It is sometimes used as an adjunctive therapy to increase oxygen delivery to ischemic tissues [21]. However, evidence is low quality, access to specialized chambers (especially for dialysis patients) is limited, and it carries logistical risks. It should never replace standard infection management, meticulous wound care, or mineral-bone treatment [22][23].

Common questions in this guide

Which specialists usually treat calciphylaxis?
Care commonly involves nephrology, dermatology or wound care, pain or palliative care, renal nutrition, and surgery. One clinician should coordinate communication while the team adjusts treatment to kidney function, wounds, mineral balance, pain, and personal goals.
Is sodium thiosulfate a cure for calciphylaxis?
Sodium thiosulfate is a commonly used treatment given outside its approved labeling for calciphylaxis, but it is not a guaranteed cure. Evidence about its effect on survival is mixed, so doctors use it as one part of a broader treatment plan and tailor dosing to the patient.
What should be monitored while I receive sodium thiosulfate?
Sodium thiosulfate can cause high-anion-gap metabolic acidosis, a dangerous buildup of acid in the blood. The treatment team may monitor bicarbonate, the anion gap, and fluid status; worsening nausea, vomiting, confusion, unusual weakness, or shortness of breath should be reported immediately.
When might a calciphylaxis wound need debridement?
Debridement removes dead or infected tissue, but the decision depends on the amount of tissue damage, infection, blood flow, pain, and overall health. Some stable, dry areas may be observed when healing potential is poor, and patients should never cut, pick, or debride a wound themselves.
How are calcium and parathyroid problems managed in calciphylaxis?
Doctors may consider cinacalcet to lower parathyroid hormone without increasing calcium, with monitoring for low blood calcium. Parathyroidectomy may be appropriate for selected patients, but its benefit for calciphylaxis is uncertain and the surgery can cause a rapid calcium drop called hungry bone syndrome.
Can hyperbaric oxygen therapy help calciphylaxis?
Hyperbaric oxygen therapy may be considered as an additional treatment to increase oxygen delivery to poorly supplied tissue. Evidence is limited, access can be difficult for people receiving dialysis, and it should not replace infection management, careful wound care, or mineral-bone treatment.

Get notified when new evidence is published on Calciphylaxis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (23)
  1. 1

    The application of MDT model for calciphylaxis management in patients with end-stage renal disease.

    Pan Y, Wang H, Ye Y, et al.

    International wound journal 2023; (20(9)):3717-3723 doi:10.1111/iwj.14265.

    PMID: 37309083
  2. 2

    An Update on Calciphylaxis.

    García-Lozano JA, Ocampo-Candiani J, Martínez-Cabriales SA, Garza-Rodríguez V

    American journal of clinical dermatology 2018; (19(4)):599-608 doi:10.1007/s40257-018-0361-x.

    PMID: 29808451
  3. 3

    Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?

    Brandenburg VM, Evenepoel P, Floege J, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(8)):1211-9 doi:10.1093/ndt/gfw025.

    PMID: 27005994
  4. 4

    Calciphylaxis: risk factors, diagnosis, and treatment.

    Nigwekar SU, Kroshinsky D, Nazarian RM, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2015; (66(1)):133-46.

    PMID: 25960299
  5. 5

    Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review.

    Riemer CA, El-Azhary RA, Wu KL, et al.

    The British journal of dermatology 2017; (177(6)):1510-1518 doi:10.1111/bjd.15702.

    PMID: 28580642
  6. 6

    Management of Penile Calciphylaxis: A Case Study.

    Zillioux JM, Geisenhoff A, Gray M

    Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society 2018; (45(6)):536-539 doi:10.1097/WON.0000000000000483.

    PMID: 30395130
  7. 7

    Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study.

    Gaisne R, Péré M, Menoyo V, et al.

    BMC nephrology 2020; (21(1)):63 doi:10.1186/s12882-020-01722-y.

    PMID: 32101140
  8. 8

    Calciphylaxis and Kidney Disease: A Review.

    Gallo Marin B, Aghagoli G, Hu SL, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2023; (81(2)):232-239 doi:10.1053/j.ajkd.2022.06.011.

    PMID: 35970430
  9. 9

    Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients.

    Peng T, Zhuo L, Wang Y, et al.

    Nephrology (Carlton, Vic.) 2018; (23(7)):669-675 doi:10.1111/nep.13081.

    PMID: 28603903
  10. 10

    Sodium thiosulfate is effective in calcific uremic arteriolopathy complicating chronic hemodialysis.

    Malbos S, Ureña-Torres P, Bardin T, Ea HK

    Joint bone spine 2016; (83(1)):89-92.

    PMID: 26494591
  11. 11

    Intravenous Sodium Thiosulphate for Calciphylaxis of Chronic Kidney Disease: A Systematic Review and Meta-analysis.

    Wen W, Portales-Castillo I, Seethapathy R, et al.

    JAMA network open 2023; (6(4)):e2310068 doi:10.1001/jamanetworkopen.2023.10068.

    PMID: 37099293
  12. 12

    Multimodality approach to treat calciphylaxis in end-stage kidney disease patients.

    Lajoie C, Ghanemi A, Bourbeau K, et al.

    Renal failure 2023; (45(2)):2256413 doi:10.1080/0886022X.2023.2256413.

    PMID: 37724534
  13. 13

    Metabolic acidosis after sodium thiosulfate infusion and the role of hydrogen sulfide.

    Hunt GM, Ryder HF

    Clinical case reports 2018; (6(8)):1595-1599 doi:10.1002/ccr3.1673.

    PMID: 30147912
  14. 14

    Profound metabolic acidosis in association with sodium thiosulfate therapy in a patient with calcific uremic arteriolopathy: a case report and literature review.

    Abdalla M, Faris ME, Saad E, et al.

    CEN case reports 2024; (13(1)):59-65 doi:10.1007/s13730-023-00801-x.

    PMID: 37273129
  15. 15

    Calciphylaxis of the Breast: A Case Report and Literature Review.

    Hall DJ, Gentile LF, Duckworth LV, et al.

    The breast journal 2016; (22(5)):568-72 doi:10.1111/tbj.12632.

    PMID: 27332900
  16. 16

    Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis.

    McCarthy JT, El-Azhary RA, Patzelt MT, et al.

    Mayo Clinic proceedings 2016; (91(10)):1384-1394 doi:10.1016/j.mayocp.2016.06.025.

    PMID: 27712637
  17. 17

    Multidisciplinary approach to calcific uremic arteriolopathy.

    Nigwekar SU

    Current opinion in nephrology and hypertension 2015; (24(6)):531-7 doi:10.1097/MNH.0000000000000175.

    PMID: 26371529
  18. 18

    The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

    Floege J, Kubo Y, Floege A, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2015; (10(5)):800-7 doi:10.2215/CJN.10221014.

    PMID: 25887067
  19. 19

    The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review.

    Deen J, Schaider H

    The Australasian journal of dermatology 2019; (60(3)):e186-e194 doi:10.1111/ajd.12992.

    PMID: 30666627
  20. 20

    Elevated Perioperative Morbidity After Parathyroidectomy for Calciphylaxis Patients: A Nationwide Retrospective Observational Study.

    Bauzon J, Perez-Soto R, Jin J, et al.

    The Journal of surgical research 2025; (314()):185-190 doi:10.1016/j.jss.2025.07.011.

    PMID: 40768885
  21. 21

    Hyperbaric oxygen therapy in patients suffering from wounds in calciphylaxis: a narrative review.

    Charaghvandi DA, Teguh DN, van Hulst RA

    Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc 2020; (47(1)):111-123 doi:10.22462/01.03.2020.12.

    PMID: 32176952
  22. 22

    Patient-Reported and Clinical Outcomes Among Patients With Calciphylaxis.

    Wen W, Krinsky S, Kroshinsky D, et al.

    Mayo Clinic proceedings. Innovations, quality & outcomes 2023; (7(1)):81-92 doi:10.1016/j.mayocpiqo.2022.12.006.

    PMID: 36712824
  23. 23

    A retrospective review of outcomes after hyperbaric oxygen therapy for the treatment of calciphylaxis.

    Biglione B, Cucka B, Iriarte C, et al.

    Journal of the American Academy of Dermatology 2024; (90(1)):45-51 doi:10.1016/j.jaad.2023.07.1031.

    PMID: 37586460

This page is for informational purposes only and does not constitute medical advice. Your nephrologist and multidisciplinary team should individualize decisions about sodium thiosulfate, wound care, surgery, and other calciphylaxis treatments.

Guide contents Calciphylaxis
Research & Literature
04 Triggers, Risk Factors, and Medication Review 06 Living with Calciphylaxis